Epigenetics mechanisms mediate the miR-125a/BRMS1 axis to regulate invasion and metastasis in gastric cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.30207593
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi:10.1016/S0140-6736(17)33326-329395269
   PubMed Web of Science ®Google Scholar
• Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018;30(1):1–12. doi:10.21147/j.issn.1000-9604.2018.01.0129545714
   PubMed Web of Science ®Google Scholar
• Song Z, Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biol. 2017;39(7): 1010428317714626. doi:10.1177/1010428317714626.
   Google Scholar
• Seraj MJ, Samant RS, Verderame MF, Welch DR. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 2000;60(11):2764–2769.10850410
   PubMed Web of Science ®Google Scholar
• Welch DR, Manton CA, Hurst DR. Breast cancer metastasis suppressor 1 (BRMS1): robust biological and pathological data, but still enigmatic mechanism of action. Adv Cancer Res. 2016;132:111–137. doi:10.1016/bs.acr.2016.05.00327613131
   PubMed Web of Science ®Google Scholar
• Kodura MA, Souchelnytskyi S. Breast carcinoma metastasis suppressor gene 1 (BRMS1): update on its role as the suppressor of cancer metastases. Cancer Metastasis Rev. 2015;34(4):611–618. doi:10.1007/s10555-015-9583-z26328523
   PubMed Web of Science ®Google Scholar
• Jie Z, Chen X, Li Z, et al. Effect of breast-cancer metastasis suppressor 1 (BRMS1) on growth and metastasis of human gastric cancer cells in vivo. Chinese Ger J Clin Oncol. 2012;11(10):592–597. doi:10.1007/s10330-011-0920-6
   Google Scholar
• Cao Y, Tan S, Tu Y, et al. MicroRNA-125a-5p inhibits invasion and metastasis of gastric cancer cells by targeting BRMS1 expression. Oncol Lett. 2018;15(4):5119–5130. doi:10.3892/ol.2018.798329552146
   PubMed Web of Science ®Google Scholar
• Guo XL, Wang YJ, Cui PL, et al. Effect of BRMS1 expression on proliferation, migration and adhesion of mouse forestomach carcinoma. Asian Pac J Trop Med. 2015;8(9):724–730. doi:10.1016/j.apjtm.2015.07.02026433658
   PubMed Web of Science ®Google Scholar
• Hirst M, Marra MA. Epigenetics and human disease. Int J Biochem Cell Biol. 2009;41(1):136–146. doi:10.1016/j.biocel.2008.09.01118852064
   PubMed Web of Science ®Google Scholar
• Mummaneni P, Shord SS. Epigenetics and oncology. Pharmacotherapy. 2014;34(5):495–505. doi:10.1002/phar.2014.34.issue-524619798
   PubMed Web of Science ®Google Scholar
• Puneet KHR, Kumari S, Tiwari S, Khanna A, Narayan G. Epigenetic mechanisms and events in gastric cancer-emerging novel biomarkers. Pathol Oncol Res. 2018;24(4):757–770. doi:10.1007/s12253-018-0410-z29552712
   PubMed Web of Science ®Google Scholar
• Panagopoulou M, Lambropoulou M, Balgkouranidou I, et al. Gene promoter methylation and protein expression of BRMS1 in uterine cervix in relation to high-risk human papilloma virus infection and cancer. %A Panagopoulou M. Tumour Biol. 2017;39(4):1010428317697557. doi:10.1177/101042831769755728381193
   PubMedGoogle Scholar
• Fan B, Dachrut S, Coral H, et al. Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer. PLoS One. 2012;7(4):e29824. doi:10.1371/journal.pone.002982422539939
   PubMed Web of Science ®Google Scholar
• Gan L, Xu M, Hua R, et al. The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter. J Hematol Oncol. 2018;11(1):9. doi:10.1186/s13045-017-0547-329335012
   PubMedGoogle Scholar
• Xu J, Wang Z, Lu W, et al. EZH2 promotes gastric cancer cells proliferation by repressing p21 expression. Pathol Res Pract. 2019;215(6):152374. doi:10.1016/j.prp.2019.03.00330952377
   PubMed Web of Science ®Google Scholar
• Alzrigat M, Jernberg-Wiklund H. The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma. RNA Dis. 2017;4:2.
   Google Scholar
• Alzrigat M, Parraga AA, Agarwal P, et al. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget. 2017;8(6):10213–10224. doi:10.18632/oncotarget.1437828052011
   PubMed Web of Science ®Google Scholar
• Wu Y, Jiang W, Wang Y, et al. Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression. PLoS One. 2012;7(8):e42976. doi:10.1371/journal.pone.004297622927944
   PubMed Web of Science ®Google Scholar
• Ma G, Liu H, Hua Q, et al. KCNMA1 cooperating with PTK2 is a novel tumor suppressor in gastric cancer and is associated with disease outcome. Mol Cancer. 2017;16(1):46. doi:10.1186/s12943-017-0613-z28231797
   PubMedGoogle Scholar
• Lin X, Li F, Xu F, et al. Aberration methylation of miR-34b was involved in regulating vascular calcification by targeting Notch1. Aging (Albany NY). 2019;11(10):3182–3197. doi:10.18632/aging.10197331129659
   PubMedGoogle Scholar
• Luo M, Li Y, Shi X, et al. Aberrant methylation of EYA4 promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma. Cancer Sci. 2018;109(6):1811–1824. doi:10.1111/cas.1361529660222
   PubMed Web of Science ®Google Scholar
• Dai H, Shen K, Yang Y, et al. PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcinoma cells. Cell death & disease. 2019;10(8):595.31395860
   PubMedGoogle Scholar
• Wu J, Long Z, Cai H, Yu S, Liu X. Homeobox B7 accelerates the cancer progression of gastric carcinoma cells by promoting epithelial-mesenchymal transition (EMT) and activating Src-FAK pathway. OncoTargets and therapy. 2019;12:3743–3751.31190875
   PubMedGoogle Scholar
• Niu Y, Ma F, Huang W, et al. Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2. Mol Cancer. 2017;16(1):5. doi:10.1186/s12943-016-0575-628069000
   PubMedGoogle Scholar
• Qi M, Hu J, Cui Y, et al. CUL4B promotes prostate cancer progression by forming positive feedback loop with SOX4. Oncogenesis. 2019;8(3):23. doi:10.1038/s41389-019-0131-530872583
   PubMedGoogle Scholar
• Nebbioso A, Tambaro FP, Dell’Aversana C, Altucci L. Cancer epigenetics: moving forward. PLoS Genet. 2018;14(6):e1007362. doi:10.1371/journal.pgen.100766429879107
   PubMed Web of Science ®Google Scholar
• Morales S, Monzo M, Navarro A. Epigenetic regulation mechanisms of microRNA expression. Biomol Concepts. 2017;8(5–6):203–212. doi:10.1515/bmc-2017-002429161231
   PubMedGoogle Scholar
• Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427–1431. doi:10.1093/bioinformatics/18.11.142712424112
   PubMed Web of Science ®Google Scholar
• Ramassone A, Pagotto S, Veronese A, Visone R. Epigenetics and microRNAs in cancer. Int J Mol Sci. 2018;19(2):459. doi:10.3390/ijms19020459
   PubMed Web of Science ®Google Scholar
• Vivian J, Rao A, Nothaft FA, et al. Rapid and efficient analysis of 20,000 RNA-seq samples with Toil. bioRxiv. 2016;062497.
   Google Scholar
• Zhou K-R, Liu S, Sun W-J, et al. ChIPBase v2.0: decoding transcriptional regulatory networks of non-coding RNAs and protein-coding genes from ChIP-seq data. Nucleic Acids Res. 2017;45(D1):D43–D50. doi:10.1093/nar/gkw96527924033
   PubMed Web of Science ®Google Scholar
• Prestridge DS. Predicting Pol II promoter sequences using transcription factor binding sites. J Mol Biol. 1995;249(5):923–932. doi:10.1006/jmbi.1995.03497791218
   PubMed Web of Science ®Google Scholar
• Pan J, Xiang Z, Dai Q, Wang Z, Liu B, Li C. Prediction of platinum-resistance patients of gastric cancer using bioinformatics. J Cell Biochem. 2019;120(8):13478–13486. doi:10.1002/jcb.2862130912200
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12–27. doi:10.1016/j.cell.2012.06.01322770212
   PubMed Web of Science ®Google Scholar
• Biswas S, Rao CM. Epigenetics in cancer: fundamentals and beyond. Pharmacol Ther. 2017;173:118–134. doi:10.1016/j.pharmthera.2017.02.01128188812
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899. doi:10.1038/nature0870020164920
   PubMed Web of Science ®Google Scholar
• Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012;6(6):567–578. doi:10.1016/j.molonc.2012.07.00722902148
   PubMed Web of Science ®Google Scholar
• Bi C, Chung TH, Huang G, et al. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget. 2015;6(28):26508–26518. doi:10.18632/oncotarget.476926164366
   PubMedGoogle Scholar
• Chen H, Xu Z. Hypermethylation-associated silencing of miR-125a and miR-125b: a potential marker in colorectal cancer. Dis Markers. 2015;2015:345080. doi:10.1155/2015/10535826693202
   PubMed Web of Science ®Google Scholar
• Kurdistani SK. Histone modifications in cancer biology and prognosis. Prog Drug Res. 2011;67:91–106.21141726
   PubMedGoogle Scholar
• Nowacka-Zawisza M, Wisnik E. DNA methylation and histone modifications as epigenetic regulation in prostate cancer (Review). Oncol Rep. 2017;38(5):2587–2596. doi:10.3892/or.2017.597229048620
   PubMed Web of Science ®Google Scholar
• Pan Y-M, Wang C-G, Zhu M, et al. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer. Mol Cancer. 2016;15(1):79. doi:10.1186/s12943-016-0561-z27938379
   PubMedGoogle Scholar
• Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006;97(6):484–491. doi:10.1111/j.1349-7006.2006.00203.x16734726
   PubMed Web of Science ®Google Scholar
• Cai GH, Wang K, Miao Q, Peng YS, Chen XY. Expression of polycomb protein EZH2 in multi-stage tissues of gastric carcinogenesis. J Dig Dis. 2010;11(2):88–93. doi:10.1111/j.1751-2980.2010.00420.x20402834
   PubMed Web of Science ®Google Scholar
• Li G, Li L, Sun Q, et al. MicroRNA-3200-5p promotes osteosarcoma cell invasion via suppression of BRMS1. Mol Cells. 2018;41(6):523–531. doi:10.14348/molcells.2018.220029890825
   PubMed Web of Science ®Google Scholar
• Sun F, Yu M, Yu J, et al. miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B. Cell Death Dis. 2018;9(5):522. doi:10.1038/s41419-018-0611-029743567
   PubMedGoogle Scholar
• Ning X, Shi Z, Liu X, et al. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Cancer Lett. 2015;359(2):198–205. doi:10.1016/j.canlet.2015.01.00525595591
   PubMed Web of Science ®Google Scholar
• Kwon H, Song K, Han C, et al. Epigenetic silencing of miRNA-34a in human cholangiocarcinoma via EZH2 and DNA methylation: impact on regulation of notch pathway. Am J Pathol. 2017;187(10):2288–2299. doi:10.1016/j.ajpath.2017.06.01428923203
   PubMed Web of Science ®Google Scholar
• Ihira K, Dong P, Xiong Y, et al. EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis. Oncotarget. 2017;8(8):13509–13520. doi:10.18632/oncotarget.1458628088786
   PubMedGoogle Scholar
• Chimonidou M, Kallergi G, Georgoulias V, Welch DR, Lianidou ES. Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells. Mol Cancer Res. 2013;11(10):1248–1257. doi:10.1158/1541-7786.MCR-13-009623744981
   PubMed Web of Science ®Google Scholar
• Balgkouranidou I, Chimonidou M, Milaki G, et al. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. Br J Cancer. 2014;110(8):2054–2062. doi:10.1038/bjc.2014.10424642624
   PubMed Web of Science ®Google Scholar
• Smith PW, Liu Y, Siefert SA, Moskaluk CA, Petroni GR, Jones DR. Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. Cancer Lett. 2009;276(2):196–203. doi:10.1016/j.canlet.2008.11.02419111386
   PubMed Web of Science ®Google Scholar
• Sheng XJ, Zhou DM, Liu Q, Lou SY, Song QY, Zhou YQ. BRMS1 inhibits expression of NF-kappaB subunit p65, uPA and OPN in ovarian cancer cells. Eur J Gynaecol Oncol. 2014;35(3):236–242.24984534
   PubMed Web of Science ®Google Scholar
• Ventura BV, Quezada C, Maloney SC, et al. Expression of the metastasis suppressor BRMS1 in uveal melanoma. Ecancermedicalscience. 2014;8:410.24688598
   PubMedGoogle Scholar